LEADER 04405nam 2201177z- 450 001 9910566462203321 005 20231214133213.0 035 $a(CKB)5680000000037759 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81172 035 $a(EXLCZ)995680000000037759 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aOncolytic Virus Immunotherapy 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (366 p.) 311 $a3-0365-2549-1 311 $a3-0365-2548-3 330 $aDear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, ?Oncolytic Virus Immunotherapy?, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. 606 $aMedicine$2bicssc 606 $aClinical & internal medicine$2bicssc 610 $aoncolytic viruses 610 $amelanoma 610 $aimmunotherapy 610 $acheckpoint inhibitors 610 $acombinatory therapy 610 $areovirus 610 $aoncolytic virus 610 $aadenovirus 610 $aoncolytic 610 $avirotherapy 610 $atargeting 610 $aimmunogenic cell death 610 $a?v?6 integrin 610 $aoncolytic adenovirus 610 $acancer immunotherapy 610 $amulti-stage 610 $aimmunostimulatory 610 $aarming 610 $aHSV-1 610 $aclinical trials 610 $anewcastle disease virus 610 $aNDV 610 $acancer 610 $aimmune checkpoint inhibitor 610 $aPD-1 610 $aPD-L1 610 $aCTLA-4 610 $atype I interferon 610 $aherpes simplex virus 610 $aretargeted virus 610 $atropism retargeting 610 $atumor 610 $acheckpoint inhibitor 610 $avaccination 610 $aantigen-agnostic vaccination 610 $aHER2 610 $aparvovirus 610 $atumor microenvironment 610 $acombination therapy 610 $aglioblastoma 610 $apancreatic cancer 610 $acolorectal cancer 610 $ameasles virus 610 $avector engineering 610 $aimmune checkpoint blockade 610 $aantitumor immune response 610 $adelivery 610 $agenetic modification 610 $abiomarkers 610 $apersonalized oncolyticvirotherapy 610 $aclass I HLA 610 $aimmunosurveillance 610 $aimmunoediting 610 $aoncogenic signaling 610 $aRAS 610 $aDNA methyltransferase inhibitor (DNMTi) 610 $aviral mimicry 610 $aepigenetic silencing 610 $aadoptive T cell therapy 610 $aCAR T cell 610 $apancreatic ductal adenocarcinoma 610 $avesicular stomatitis virus 610 $asmall molecule 610 $acancer immune therapy 610 $acancer therapy 615 7$aMedicine 615 7$aClinical & internal medicine 700 $aMarchini$b Antonio$4edt$01309617 702 $aIlkow$b Carolina S$4edt 702 $aMelcher$b Alan$4edt 702 $aMarchini$b Antonio$4oth 702 $aIlkow$b Carolina S$4oth 702 $aMelcher$b Alan$4oth 906 $aBOOK 912 $a9910566462203321 996 $aOncolytic Virus Immunotherapy$93029458 997 $aUNINA